In this review, we explore the diverse factors contributing to the variability in metformin response among T2D individuals, with a particular focus on recent advancements in genomics, metabolomics, and microbiomics
Medical Writing/Editorial Assistance The authors acknowledge the medical writing and editorial assistance of Aislinn Harkin and Beverly La Ferla, of Ashfield MedComms, an Inizio company (funded by Novo Nordisk Inc.)
D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T
The findings on antidepressants by Yildiz et al [7] are in line with a prior systematic review and meta-analysis from 2016 focusing on randomised, double-blind, placebo-controlled trials of second-generation antidepressants adjunctive to a mood stabiliser or an antipsychotic in patients with acute bipolar depression [14]
Employers also continue to receive pressure to cover GLP-1s for weight loss